Economic Implications of Potential Drug–Drug Interactions in Chronic Pain Patients

Robert Taylor Jr; Joseph V Pergolizzi Jr; R Amy Puenpatom; Kent H Summers

Disclosures

Expert Rev Pharmacoeconomics Outcomes Res. 2013;13(6):725-734. 

In This Article

Prevalence of DDEs

The prevalence of DDEs in the general chronic noncancer pain patient, OA and cLBP patient were assessed in five studies (Table 1). The prevalence of DDEs in the general chronic noncancer pain patient were estimated to be approximately 35%.[31] In addition, the prevalence rate of DDEs in specific chronic pain conditions such as OA and cLBP were estimated to be 26 and 27%, respectively.[27,28] These studies indicate that DDEs are a widespread problem in patients with chronic pain.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....